Palisade Bio Completes Dosing in Phase 1a Portion of Ongoing Phase 1a/b Study of PALI-2108

Core Insights - Palisade Bio, Inc. has completed enrollment and dosing in all Phase 1a single ascending dose (SAD) and multiple ascending dose (MAD) cohorts for PALI-2108, aimed at treating Ulcerative Colitis (UC) [1][2][3] - Preliminary data indicates no serious adverse events (SAEs) or treatment-emergent adverse events (TEAEs) related to laboratory values or EKGs, demonstrating the drug's safety and tolerability [1][2][3] - The company is on track to report topline data from the Phase 1a portion of the study by the end of May 2025, with ongoing screening for the Phase 1b UC cohort [1][2][3] Study Details - The Phase 1a/b study aims to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of PALI-2108 in healthy volunteers and UC patients [4] - Biomarkers such as serum high sensitivity C-reactive protein (hsCRP) and fecal calprotectin (CalPro) will be used to assess the drug's effects [4] - PALI-2108 is a new chemical entity that has not been previously administered to humans, differentiating it from other PDE4 inhibitors [4] Company Overview - Palisade Bio is focused on developing novel therapeutics for autoimmune, inflammatory, and fibrotic diseases, aiming to transform the treatment landscape with targeted approaches [6]